West Pharmaceutical Services, Inc. (WST), a supplier of injectable packaging and delivery components, reported a strong start to 2026 with double-digit revenue and earnings growth, prompting the company to raise its full-year guidance.
Net sales for the first quarter rose 21% to $844.9 million, compared with $698.0 million in the prior-year period.
Organic sales increased 15.3%, driven by continued momentum in the company's High-Value Product (HVP) portfolio.
Diluted EPS climbed 56% to $1.92, up from $1.23 a year earlier. Adjusted diluted EPS increased 46.9% to $2.13, compared with $1.45 in Q1 2025.
Operating cash flow totaled $89.9 million, while free cash flow reached $47.2 million.
West repurchased 1.2 million shares for $297.6 million during the quarter at an average price of $243.57 per share.
Segment Performance
Proprietary Products, the company's largest segment, generated $694.3 million, up 23.3% year over year.
- High-Value Product (HVP) Components revenue rose 29.6% to $409.3 million, supported by strong demand for Westar and NovaPure products, compared to $315.9 million, in the prior year.
-HVP Delivery Devices grew 29% to $123.6 million, compared to $95.8 million, in the prior year, driven by self-injection platforms and Daikyo Crystal Zenith.-Standard Products increased 6.7% to $161.4 million, up from $151.3 million in the prior year.
West Vantage, formerly Contract-Manufactured Products, delivered $150.6 million, up 11.6%, supported by higher demand for self-injection devices used in obesity and diabetes therapies.
Updated 2026 Outlook
Following the strong quarter, West raised its full-year 2026 guidance:
-Net sales: now expected between $3.295 billion and $3.350 billion compared to $3.074 billion from FY 2025
-Adjusted diluted EPS: increased to $8.40 to $8.75, compared to $7.29 from FY 2025-Capital spending: unchanged at $250 million to $275 million, compared to $285.9 million from FY2025.
For Q2 2026, West expects revenue of $830 million to $850 million, compared to $766.5 million from the previous-year quarter.
And adjusted EPS of $2.05 to $2.12, compared to $1.84 from Q2 2025.
WST has traded between $199.89 and $322.34 over the past year. The stock is currently trading at $312.38, up 13.95%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.